Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of May 2025
Date Filed: May 12, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, this report focuses on corporate governance and ownership changes rather than operational financial results.
Material Changes
- Ownership Change: The filing includes Exhibit 99.1, which details a "Change in substantial holding."
- Registration Statements: This report is incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves primarily as a notification of the substantial holding change and incorporation into existing registration statements.
Investor Verification Checklist
- Review Exhibit 99.1 to determine the specific nature and magnitude of the change in substantial holding.
- Verify the impact of this ownership change on the company's control structure and future capital raising capabilities under the referenced Form S-8 and Form F-3 registration statements.
- Confirm the company's continued status as a development stage enterprise and its current cash runway, as no financial data is included in this specific filing.